HLB has taken a step closer to the global commercialization of its anticancer treatment Rivoceranib as it secured statistical significance in Phase 3 global clinical trials of the drug, according to the local biotech company, Sunday.
Please refer to the following website for further details:
http://www.koreatimes.co.kr/www/nation/2022/05/113_329156.html